消化不良藥物市場：按類型、藥物類型、分銷管道分類 - 全球預測 2025-2030

2023年消化不良治療市場價值為85.8億美元，預計到2024年將達到90.1億美元，複合年成長率為5.12%，到2030年將達到121.8億美元。

胃腸道藥物是更廣泛的胃腸道藥物市場的重要組成部分，旨在控制胃部不適、腹脹和噁心等症狀。全球功能性消化不良的高盛行率凸顯了對這些藥物的需求，而不良飲食和壓力等生活方式因素又加劇了這種情況。這些藥物用於醫院、診所和居家醫療機構，以幫助短期症狀緩解和慢性病的長期管理。市場成長的主要促進因素包括人口老化、胃腸道疾病盛行率上升以及配方和藥物輸送系統的進步。新興市場的醫療保健意識和獲取機會的提高也是市場擴張的沃土。開發新的、更有效的化合物和以患者為中心的解決方案，包括非處方藥，代表著一個重大機遇，可以利用消費者對更容易獲得的醫療保健日益成長的偏好。然而，藥物開發的高成本、嚴格的監管流程和潛在的副作用等限制因素構成了重大挑戰。此外，來自替代療法和營養食品的競爭也阻礙了市場成長。為了克服這些挑戰，創新應側重於精準醫療以及人工智慧主導的診斷和個人化治療計劃等數位健康技術的整合，從而提高藥物療效和患者依從性。鑑於對整體醫療保健解決方案的需求不斷成長，投資強大的研發策略以實現益生菌和天然萃取物的藥物組合多樣化可能是我的策略重點。市場動態是動態的和競爭性的，需要與醫療保健專業人員和患者持續接觸，以確定未滿足的需求並適應不斷變化的消費者偏好。為了保持優勢，公司應該投資消費者教育並與監管機構建立牢固的工作關係，以促進更順利的市場進入和擴張。

市場動態：快速發展的消化不良藥物市場的關鍵市場洞察

消化不良藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

• 市場促進因素
  • 消化不良的盛行率在世界各地迅速增加
  • 支持加速醫藥品認證過程的政府政策
  • 投資改良藥物輸送和包裝技術
• 市場限制因素
  • 產品召回與安全問題
• 市場機會
  • 透過共同開發和官民合作關係擴大發展
  • 提高藥效的研發進展
• 市場挑戰
  • 假藥的可用性

波特五力：駕馭消化不良藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解消化不良藥物市場的外部影響

外部宏觀環境因素在塑造消化不良藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解消化不良治療市場的競爭狀況

對消化不良治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣消化不良藥物市場供應商的績效評估

FPNV定位矩陣是評估消化不良藥物市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃消化不良治療藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，消化不良治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

• 市場動態
  • 促進因素
    • 全球消化不良盛行率飆升
    • 支持加速藥品核准流程的政府政策
    • 投資改良藥物輸送和包裝技術
  • 抑制因素
    • 產品召回與安全問題
  • 機會
    • 透過聯合開發和公私合營進行擴張
    • 提高藥物療效的研發進展
  • 任務
    • 假藥的可用性
• 市場區隔分析
  • 類型：功能性消化不良的廣泛發生和轉向更個性化的藥物
  • 藥物類型：擴大使用質子幫浦阻斷劑和H2受體阻斷劑來治療消化不良
• 波特五力分析
• PESTEL分析
  • 政治的
  • 經濟
  • 社群
  • 技術的
  • 合法地
  • 環境

第6章消化不良治療藥物市場：依類型

• 功能性消化不良
• 器質性消化不良

第7章消化不良治療藥物市場（按類型）

• 抑酸劑
• 制酸劑
• 抗生素
• 抗驚厥藥
• 抗憂鬱症
• 西咪替丁
• 法莫替丁
• H2拮抗劑
• 尼扎替丁
• 消化促進劑
• 質子幫浦抑制劑
• Rabeprazole
• 贊塔克

第8章消化不良治療藥物市場：按分銷管道

• 醫院藥房
• 網路藥房
• 零售藥房

第9章北美及南美消化不良藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第10章亞太消化不良治療市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第11章 歐洲、中東和非洲消化不良治療市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第12章競爭格局

• 2023 年市場佔有率分析
• FPNV 定位矩陣，2023
• 競爭情境分析
  • 突破性 FDA核准，Fathom Pharmaceuticals 推出 VOQUEZNA，治療糜爛性胃食道逆流症
  • 剪切機-Smith推出法莫替丁口服混懸劑是美國學名藥市場的策略性舉措。
  • Mark Sands Pharma非專利藥法莫替丁錠獲得美國FDA核准
• 戰略分析和建議

公司名單

• Abbott Laboratories
• ANI Pharmaceuticals, Inc.
• AstraZeneca PLC
• Bayer AG
• Cadila Pharmaceuticals
• Dr Reddy's Laboratories Ltd
• Haleon PLC
• Intas Pharmaceuticals Ltd.
• Lupin Ltd.
• Mankind Pharma
• Pfizer Inc.
• Prestige Consumer Healthcare Inc.
• Procter & Gamble Company
• Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Themis Medicare Ltd.
• Torrent Pharmaceuticals Ltd.

The Dyspepsia Drug Market was valued at USD 8.58 billion in 2023, expected to reach USD 9.01 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 12.18 billion by 2030.

Dyspepsia drugs form a crucial segment within the broader gastrointestinal therapeutics market, aimed at managing symptoms like stomach discomfort, bloating, and nausea. The necessity for these drugs is underscored by the high prevalence of functional dyspepsia worldwide, exacerbated by lifestyle factors such as poor diet and stress. These drugs find applications across hospitals, clinics, and homecare settings, serving both short-term symptomatic relief and long-term management of chronic conditions. Key drivers of market growth include an aging population, the rising incidence of gastrointestinal disorders, and ongoing advancements in drug formulations and delivery systems. Increasing healthcare awareness and access in emerging markets also provide fertile ground for market expansion. A prominent opportunity lies in the development of novel, more efficacious drug compounds and patient-centered solutions, including over-the-counter options, potentially tapping into the growing consumer preference for accessible healthcare solutions. However, limitations like the high cost of drug development, stringent regulatory processes, and potential side effects pose significant challenges. Additionally, market growth is hampered by competition from alternative therapies and dietary supplements. To overcome these challenges, innovation should focus on precision medicine and the integration of digital health technologies, such as AI-driven diagnostics and personalized treatment plans, thus enhancing drug efficacy and patient adherence. Investing in robust R&D strategies to diversify the drug portfolio with probiotics and natural extracts could be a strategic pivot, considering the rising demand for holistic healthcare solutions. The nature of the dyspepsia drug market is dynamic and competitive, necessitating continuous engagement with healthcare professionals and patients to identify unmet needs and adapt to evolving consumer preferences. To maintain an edge, companies should invest in consumer education and build strong collaborations with regulatory bodies to facilitate smoother market entry and expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dyspepsia Drug Market

The Dyspepsia Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Surging prevalence of Dyspepsia worldwide
  • Government policies favoring faster drug approval processes
  • Investment in improved drug delivery and packaging technologies
• Market Restraints
  • Product recall and safety concerns
• Market Opportunities
  • Expansion through collaborative development and public-private partnerships
  • Advancements in research and development for enhanced drug efficacy
• Market Challenges
  • Availability of the counterfeit drugs

Porter's Five Forces: A Strategic Tool for Navigating the Dyspepsia Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dyspepsia Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dyspepsia Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dyspepsia Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dyspepsia Drug Market

A detailed market share analysis in the Dyspepsia Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dyspepsia Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dyspepsia Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dyspepsia Drug Market

A strategic analysis of the Dyspepsia Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dyspepsia Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Cadila Pharmaceuticals, Dr Reddy's Laboratories Ltd, Haleon PLC, Intas Pharmaceuticals Ltd., Lupin Ltd., Mankind Pharma, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Dyspepsia Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Functional Dyspepsia and Organic Dyspepsia.
• Based on Drug Type, market is studied across Acid Reducer, Antacids, Antibiotics, Anticonvulsant, Antidepressants, Cimetidine, Famotidine, H2 Antagonist, Nizatidine, Prokinetic agent, Proton-pump Inhibitor, Rabeprazole, and Zantac.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Surging prevalence of Dyspepsia worldwide
    • 5.1.1.2. Government policies favoring faster drug approval processes
    • 5.1.1.3. Investment in improved drug delivery and packaging technologies
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall and safety concerns
  • 5.1.3. Opportunities
    • 5.1.3.1. Expansion through collaborative development and public-private partnerships
    • 5.1.3.2. Advancements in research and development for enhanced drug efficacy
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of the counterfeit drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Wide occurrence of functional dyspepsia with the shift towards more personalized drugs
  • 5.2.2. Drug Type: Growing utilization of proton pump inhibitors and H2 receptor blockers for dyspepsia treatment
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dyspepsia Drug Market, by Type

• 6.1. Introduction
• 6.2. Functional Dyspepsia
• 6.3. Organic Dyspepsia

7. Dyspepsia Drug Market, by Drug Type

• 7.1. Introduction
• 7.2. Acid Reducer
• 7.3. Antacids
• 7.4. Antibiotics
• 7.5. Anticonvulsant
• 7.6. Antidepressants
• 7.7. Cimetidine
• 7.8. Famotidine
• 7.9. H2 Antagonist
• 7.10. Nizatidine
• 7.11. Prokinetic agent
• 7.12. Proton-pump Inhibitor
• 7.13. Rabeprazole
• 7.14. Zantac

8. Dyspepsia Drug Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Dyspepsia Drug Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Dyspepsia Drug Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Dyspepsia Drug Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Breakthrough FDA Approval, Phathom Pharmaceuticals Unveils VOQUEZNA for Erosive GERD Treatment
  • 12.3.2. Launch of Upsher-Smith's Famotidine for Oral Suspension, A Strategic Move in the U.S. Generic Drug Market
  • 12.3.3. Marksans Pharma Secures USFDA Approval for Generic Famotidine Tablets
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ANI Pharmaceuticals, Inc.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Cadila Pharmaceuticals
• 6. Dr Reddy's Laboratories Ltd
• 7. Haleon PLC
• 8. Intas Pharmaceuticals Ltd.
• 9. Lupin Ltd.
• 10. Mankind Pharma
• 11. Pfizer Inc.
• 12. Prestige Consumer Healthcare Inc.
• 13. Procter & Gamble Company
• 14. Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International
• 15. Sanofi SA
• 16. Sun Pharmaceutical Industries Ltd.
• 17. Takeda Pharmaceutical Company Limited
• 18. Themis Medicare Ltd.
• 19. Torrent Pharmaceuticals Ltd.

LIST OF FIGURES

• FIGURE 1. DYSPEPSIA DRUG MARKET RESEARCH PROCESS
• FIGURE 2. DYSPEPSIA DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DYSPEPSIA DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DYSPEPSIA DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FUNCTIONAL DYSPEPSIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORGANIC DYSPEPSIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ACID REDUCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTICONVULSANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETIC AGENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON-PUMP INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ZANTAC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. CANADA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. CHINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. INDIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. ITALY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. POLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. QATAR DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 151. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 154. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 156. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023